CLINICAL_TRIALS
trial_result
· 2025-04-16
Clinical Trial Update: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma [Phase 2]
Summary
A Phase 2 clinical trial evaluating the combination of zanubrutinib and rituximab for indolent mantle cell lymphoma is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University College, London | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING